Jagsi Reshma, Momoh Adeyiza O, Qi Ji, Hamill Jennifer B, Billig Jessica, Kim Hyungjin M, Pusic Andrea L, Wilkins Edwin G
Department of Radiation Oncology, Section of Plastic Surgery, Center for Statistical Consultation and Research, University of Michigan, Ann Arbor, MI; Division of Plastic and Reconstructive Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
J Natl Cancer Inst. 2018 Feb 1;110(2):157-65. doi: 10.1093/jnci/djx148.
Patients considering postmastectomy radiation and reconstruction require information regarding expected outcomes to make preference-concordant decisions.
A prospective multicenter cohort study of women diagnosed with breast cancer at 11 centers between 2012 and 2015 compared complications and patient-reported outcomes of 622 irradiated and 1625 unirradiated patients who received reconstruction. Patient characteristics and outcomes between irradiated and unirradiated patients were analyzed using ttests for continuous variables and chi-square tests for categorical variables. Multivariable mixed-effects regression modelsassessed the impact of reconstruction type and radiotherapy on outcomes after adjusting for relevant covariates. All statistical tests were two-sided.
Autologous reconstruction was more commonly received by irradiated patients (37.9% vs 25.0%, P < .001). Immediate reconstruction was less common in irradiated patients (83.0% vs 95.7%, P < .001). At least one breast complication had occurred by two years in 38.9% of irradiated patients with implant reconstruction, 25.6% of irradiated patients with autologous reconstruction, 21.8% of unirradiated patients with implant reconstruction, and 28.3% of unirradiated patients with autologous reconstruction. Multivariable analysis showed bilateral treatment and higher body mass index to be predictive of developing a complication, with a statistically significant interaction between radiotherapy receipt and reconstruction type. Among irradiated patients, autologous reconstruction was associated with a lower risk of complications than implant-based reconstruction at two years (odds ratio [OR] = 0.47, 95% confidence interval [CI] = 0.27 to 0.82, P = .007); no between-procedure difference was found in unirradiated patients. The interaction was also statistically significant for satisfaction with breasts at two years (P = .002), with larger adjusted difference in satisfaction between autologous vs implant approaches (63.5, 95% CI = 55.9 to 71.1, vs 47.7, 95% CI = 40.2 to 55.2, respectively) in irradiated patients than between autologous vs implant approaches (67.6, 95% CI = 60.3 to 74.9, vs 60.5, 95% CI = 53.6 to 67.4) in unirradiated patients.
Autologous reconstruction appears to yield superior patient-reported satisfaction and lower risk of complications than implant-based approaches among patients receiving postmastectomy radiotherapy.
考虑接受乳房切除术后放疗和重建的患者需要了解预期结果,以便做出符合个人偏好的决策。
一项前瞻性多中心队列研究,对2012年至2015年间在11个中心被诊断为乳腺癌的女性进行研究,比较了622例接受放疗和1625例未接受放疗且接受重建的患者的并发症及患者报告的结果。使用t检验分析连续变量,使用卡方检验分析分类变量,以比较接受放疗和未接受放疗患者的患者特征及结果。多变量混合效应回归模型在调整相关协变量后评估重建类型和放疗对结果的影响。所有统计检验均为双侧检验。
接受放疗的患者更常采用自体组织重建(37.9%对25.0%,P<.001)。即刻重建在接受放疗的患者中较少见(83.0%对95.7%,P<.001)。在接受植入物重建的放疗患者中,38.9%在两年内至少发生了一种乳房并发症;在接受自体组织重建的放疗患者中,这一比例为25.6%;在未接受放疗且接受植入物重建的患者中,为21.8%;在未接受放疗且接受自体组织重建的患者中,为28.3%。多变量分析显示,双侧治疗和较高的体重指数可预测发生并发症,放疗与重建类型之间存在统计学显著的相互作用。在接受放疗的患者中,自体组织重建与两年内较低的并发症风险相关,相比基于植入物的重建(比值比[OR]=0.47,95%置信区间[CI]=0.27至0.82,P=.007);在未接受放疗的患者中,未发现不同重建方式之间存在差异。这种相互作用在两年时对乳房满意度也具有统计学显著性(P=.002),接受放疗患者中自体组织与植入物重建方式之间调整后的满意度差异更大(分别为63.5,95%CI=55.9至71.1,对47.7,95%CI=40.2至55.2),高于未接受放疗患者中自体组织与植入物重建方式之间的差异(67.6,95%CI=60.3至74.9,对60.5,95%CI=53.6至67.4)。
在接受乳房切除术后放疗的患者中,与基于植入物的重建方式相比,自体组织重建似乎能带来更高的患者报告满意度和更低的并发症风险。